To download the latest issue
Feb 20th, 2013
London Business Angels investment helps Sphere Fluidics close £1.6m early stage funding round
Early stage, Cambridge based, life science company, Sphere Fluidics, has closed a £1.6m funding round which included a £133k investment by a syndicate of London Business Angels and its EIS Approved Roundtable Syndicate Fund 2012.
The company is commercialising a highly innovative single cell analysis technology which can accelerate new bio-pharmaceutical discovery, generate stem cell therapies and enable novel studies on single cell diseases such as cancer. This picodroplet technology, using a microfluidic chip, can perform up to eight million single cell tests per day and has already been used by a number of Blue Chip clients. This new round of substantial funding will enable the company to expand its management resources, relocate to a new facility and accelerate sales growth.
More MEDTECH news